image credit- shutterstock
Cardio Diagnostics Holdings Inc., a US-based artificial intelligence (AI)-powered precision cardiovascular medicine company, has announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company’s intellectual property portfolio.
The patent, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,” is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF).
The Japanese patent further strengthens Cardio Diagnostics’ global IP strategy and adds to its robust portfolio of issued patents in the United States, Europe, Australia, India, and China, covering core technologies that helped yield the company’s clinical solutions.
“Receiving this patent in Japan marks a critical milestone in our mission to globalise our precision cardiovascular medicine platform,” said Meesha Dogan, Ph.D., CEO of Cardio Diagnostics. “As cardiovascular disease continues to rise in prevalence worldwide, the ability to offer AI-powered, methylation- and genetics-based diagnostics in international markets like Japan represents a major step forward in improving early detection and prevention of heart disease.”
Marie Kerbeshian, Ph.D., Executive Director of the UIRF said, “Cardio Diagnostics continues to demonstrate the global relevance of its technology, and we look forward to the impact it will have in advancing cardiovascular medicine across borders.”
The Japanese patent protects Cardio Diagnostics’ novel methods and compositions that enable the detection of cardiovascular disease risk and presence using epigenetic and genetic biomarkers interpreted through advanced machine learning algorithms. This issuance underscores the global applicability of the Company’s pioneering approach to heart disease prevention.
